ANDA Sponsors Get Some Relief on New Stability Requirements
This article was originally published in The Gold Sheet
Executive Summary
FDA still expects rush of ANDA submissions before new stability requirements take effect June 20, but agency has eliminated some tests and reduced some batch sizes in response to industry comments.
You may also be interested in...
ANDAs To Include Six Months Of Stability Test Data Under FDA Draft Guidance
The agency advises sponsors to follow the stability testing recommendations in the International Conference on Harmonization guidances; three companies submit comments seeking clarification from FDA.
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.